SG11201403010TA - Multiplex immuno screening assay - Google Patents

Multiplex immuno screening assay

Info

Publication number
SG11201403010TA
SG11201403010TA SG11201403010TA SG11201403010TA SG11201403010TA SG 11201403010T A SG11201403010T A SG 11201403010TA SG 11201403010T A SG11201403010T A SG 11201403010TA SG 11201403010T A SG11201403010T A SG 11201403010TA SG 11201403010T A SG11201403010T A SG 11201403010TA
Authority
SG
Singapore
Prior art keywords
screening assay
multiplex immuno
immuno screening
multiplex
assay
Prior art date
Application number
SG11201403010TA
Inventor
Jean-Claude Manuguerra
Jessica Vanhomwegen
Philippe Despres
Sylvie Paulous
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/072387 external-priority patent/WO2012076715A1/en
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of SG11201403010TA publication Critical patent/SG11201403010TA/en

Links

Classifications

    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B27/00—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00
    • G02B27/01—Head-up displays
    • G02B27/017—Head mounted
    • G02B27/0172—Head mounted characterised by optical features
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B27/00—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00
    • G02B27/0081—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00 with means for altering, e.g. enlarging, the entrance or exit pupil
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B27/00—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00
    • G02B27/42—Diffraction optics, i.e. systems including a diffractive element being designed for providing a diffractive effect
    • G02B27/4272—Diffraction optics, i.e. systems including a diffractive element being designed for providing a diffractive effect having plural diffractive elements positioned sequentially along the optical path
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B5/00—Optical elements other than lenses
    • G02B5/18—Diffraction gratings
    • G02B5/1814—Diffraction gratings structurally combined with one or more further optical elements, e.g. lenses, mirrors, prisms or other diffraction gratings
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/0001—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems
    • G02B6/0011—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems the light guides being planar or of plate-like form
    • G02B6/0013—Means for improving the coupling-in of light from the light source into the light guide
    • G02B6/0015—Means for improving the coupling-in of light from the light source into the light guide provided on the surface of the light guide or in the bulk of it
    • G02B6/0016—Grooves, prisms, gratings, scattering particles or rough surfaces
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/0001—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems
    • G02B6/0011—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems the light guides being planar or of plate-like form
    • G02B6/0033—Means for improving the coupling-out of light from the light guide
    • G02B6/0035—Means for improving the coupling-out of light from the light guide provided on the surface of the light guide or in the bulk of it
    • G02B6/0038—Linear indentations or grooves, e.g. arc-shaped grooves or meandering grooves, extending over the full length or width of the light guide
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T19/00—Manipulating 3D models or images for computer graphics
    • G06T19/006—Mixed reality
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B27/00—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00
    • G02B27/01—Head-up displays
    • G02B27/0101—Head-up displays characterised by optical features
    • G02B2027/0123—Head-up displays characterised by optical features comprising devices increasing the field of view
    • G02B2027/0125—Field-of-view increase by wavefront division
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B27/00—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00
    • G02B27/01—Head-up displays
    • G02B27/017—Head mounted
    • G02B27/0172—Head mounted characterised by optical features
    • G02B2027/0174—Head mounted characterised by optical features holographic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Computer Graphics (AREA)
  • Computer Hardware Design (AREA)
  • General Engineering & Computer Science (AREA)
  • Software Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201403010TA 2011-12-09 2012-12-10 Multiplex immuno screening assay SG11201403010TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2011/072387 WO2012076715A1 (en) 2010-12-09 2011-12-09 Mgmt-based method for obtaining high yield of recombinant protein expression
US201261642924P 2012-05-04 2012-05-04
PCT/EP2012/074986 WO2013083847A2 (en) 2011-12-09 2012-12-10 Multiplex immuno screening assay

Publications (1)

Publication Number Publication Date
SG11201403010TA true SG11201403010TA (en) 2014-07-30

Family

ID=49514226

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201403010TA SG11201403010TA (en) 2011-12-09 2012-12-10 Multiplex immuno screening assay
SG11201407167RA SG11201407167RA (en) 2012-05-04 2013-05-03 Multiplex immuno screening assay

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201407167RA SG11201407167RA (en) 2012-05-04 2013-05-03 Multiplex immuno screening assay

Country Status (15)

Country Link
US (5) US9638692B2 (en)
EP (2) EP2788478B1 (en)
JP (2) JP6215223B2 (en)
KR (2) KR102007061B1 (en)
CN (2) CN104114697A (en)
AU (2) AU2012350229B2 (en)
BR (2) BR112014013745B1 (en)
CA (2) CA2857998C (en)
DK (1) DK2788478T3 (en)
ES (1) ES2648899T3 (en)
MX (2) MX349562B (en)
NO (1) NO2788478T3 (en)
NZ (1) NZ701380A (en)
SG (2) SG11201403010TA (en)
WO (2) WO2013083847A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107090441A (en) * 2010-12-09 2017-08-25 巴斯德研究所 The method based on MGMT for obtaining high yield expression of recombinant proteins
JP6215223B2 (en) 2011-12-09 2017-10-18 アンスティテュ・パストゥール Multiplex immunoscreening assay
GB201210226D0 (en) * 2012-06-11 2012-07-25 Univ St Andrews Vaccine
WO2014045254A2 (en) 2012-09-23 2014-03-27 Erasmus University Medical Center Rotterdam Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor
WO2014049436A1 (en) * 2012-09-27 2014-04-03 Idexx Laboratories, Inc. Method of detection of schmallenberg virus (sbv) and kit
WO2014164697A1 (en) * 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
WO2014154336A1 (en) * 2013-03-26 2014-10-02 Iffmedic Gmbh Microtiter plate-based microarray
CN103472221A (en) * 2013-08-12 2013-12-25 南昌大学 Method for marking salbutamol polyclonal antibody by fluorescent microsphere
AU2014354797C1 (en) 2013-11-29 2018-02-01 Inovio Pharmaceuticals, Inc. MERS-CoV vaccine
EP3114482B1 (en) 2014-03-07 2020-10-07 The Regents of the University of California Devices for integrating analyte extraction, concentration and detection
KR102268785B1 (en) 2014-11-27 2021-06-25 킴벌리-클라크 월드와이드, 인크. Devices and methods for detecting norovirus on surfaces
CN104844710B (en) * 2015-04-13 2018-02-02 西北大学 The preparation method and application of the compound resins of oriented immobilization PEGA
CN108780081B (en) 2015-08-10 2021-04-09 Essenlix公司 Simplified-procedure, small-sample, rapid, easy-to-use bio/chemical analysis apparatus and method
US11287426B2 (en) 2015-09-04 2022-03-29 The Regents Of The University Of California Methods and devices for analyte collection, extraction, concentration, and detection for clinical applications
CN105368873A (en) * 2015-11-23 2016-03-02 艾军 Preparation method, identification method and application of baculovirus for expressing Schmallenberg virus (SBV) recombination N gene
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
CN105548540A (en) * 2015-12-29 2016-05-04 中国医学科学院医学生物学研究所 Common detection kit for I-IV type dengue fever viruses
KR20190003471A (en) 2016-02-25 2019-01-09 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 New vaccine against Zika virus
EP3229024A1 (en) * 2016-04-08 2017-10-11 Viramed Biotech AG Zika virus diagnosis
EP3469365B1 (en) 2016-06-09 2022-12-07 The Regents of the University of California Biomarker concentration and signal amplification for use in paper-based immunoassays
US11327075B2 (en) * 2016-08-22 2022-05-10 The Regents Of The University Of California Hydrogel platform for aqueous two-phase concentration of a target to enhance its detection
US10012645B2 (en) * 2016-08-24 2018-07-03 The Florida International University Board Of Trustees Rapid zika virus detection using nano-enabled electrochemical sensing system
US11651866B2 (en) * 2016-10-17 2023-05-16 Reliant Immune Diagnostics, Inc. System and method for real-time insurance quote in response to a self-diagnostic test
US12009078B2 (en) 2016-10-17 2024-06-11 Reliant Immune Diagnostics, Inc. System and method for medical escalation and intervention that is a direct result of a remote diagnostic test
US11802868B2 (en) 2016-10-17 2023-10-31 Reliant Immune Diagnostics, Inc. System and method for variable function mobile application for providing medical test results
US11107585B2 (en) 2016-10-17 2021-08-31 Reliant Immune Diagnostics, Inc System and method for a digital consumer medical wallet and storehouse
US11693002B2 (en) 2016-10-17 2023-07-04 Reliant Immune Diagnostics, Inc. System and method for variable function mobile application for providing medical test results using visual indicia to determine medical test function type
US10902951B2 (en) 2016-10-17 2021-01-26 Reliant Immune Diagnostics, Inc. System and method for machine learning application for providing medical test results using visual indicia
US11579145B2 (en) 2016-10-17 2023-02-14 Reliant Immune Diagnostics, Inc. System and method for image analysis of medical test results
US9857372B1 (en) 2016-10-17 2018-01-02 Reliant Immune Diagnostics, LLC Arbovirus indicative birth defect risk test
EP3361256A1 (en) * 2017-02-08 2018-08-15 Fundación para la Investigación Médica Aplicada In vitro method for the diagnosis of lung cancer
CN108503697B (en) * 2017-02-27 2023-03-31 中国科学院上海巴斯德研究所 Zika virus subunit vaccine expressed by drosophila cells
CN107102144A (en) * 2017-03-16 2017-08-29 深圳市梓健生物科技有限公司 Fluorescent quantitation immuno-chromatographic test paper strip of quick detection zika virus NS1 albumen and preparation method thereof
US11209427B2 (en) 2017-03-27 2021-12-28 The Regents Of The University Of California Semi-quantitative lateral-flow immunoassay for the detection of CSF leaks
EP3615554A1 (en) * 2017-04-26 2020-03-04 Roche Diagnostics GmbH Soluble and immunoreactive zika virus ns1 polypeptides
CN107287347B (en) * 2017-05-09 2020-12-25 广州机场出入境检验检疫局综合技术服务中心 Real-time fluorescence reverse transcription PCR (polymerase chain reaction) detection primer, probe, detection kit and detection method for hepatitis E virus
RU2661085C1 (en) * 2017-06-01 2018-07-11 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Recombinant proteins containing antigenic epitopes of proteins core, small envelope, ns2a and prem of zika virus, and complex antigen containing specified proteins which are used as a component of the immunoenzymometric test system for the identification of antibodies classes g and m to zika virus
WO2019039557A1 (en) * 2017-08-24 2019-02-28 富士レビオ株式会社 Method and kit for detecting zika virus
WO2019055971A2 (en) * 2017-09-18 2019-03-21 Carrera Bioscience Inc. Multiplex enteric assay and methods of use thereof
JP6939535B2 (en) * 2017-12-27 2021-09-22 トヨタ自動車株式会社 Vehicle photography equipment and heating equipment
KR102198342B1 (en) * 2019-05-22 2021-01-04 연세대학교 산학협력단 Method of screening antibody and antibody screening system using the same
BR112022005687A2 (en) * 2019-09-30 2022-06-21 Gilead Sciences Inc Vaccines against hbv and methods to treat hbv
CN111214259B (en) * 2019-11-29 2024-08-06 重庆大学 Gastric juice sampling capsule
IL296617A (en) * 2020-03-20 2022-11-01 Biontech Us Inc Coronavirus vaccines and methods of use
WO2021194540A1 (en) * 2020-03-23 2021-09-30 Baseline Viral Diagnostics, Inc. Methods, systems, and a kit for detection, diagnosis, monitoring and treatment of covid-19
JP2023524007A (en) * 2020-04-28 2023-06-08 アヴィアーナ モレキュラー テクノロジーズ，エルエルシー Compositions and surface acoustic wave-based methods for identifying infectious diseases
EP4146343A4 (en) * 2020-05-07 2024-05-29 Bio-Rad Laboratories, Inc. Sars-cov-2 immunoassay and materials therefor
WO2021236050A1 (en) 2020-05-18 2021-11-25 Baseline Global, Inc. Assay device, system, method, and kit
AU2021277232A1 (en) * 2020-05-19 2022-11-24 Aditxt, Inc. Double-multiplex assay for multiple immunoglobulin isotypes
WO2021247398A1 (en) * 2020-05-30 2021-12-09 Pangolin Llc Systems and methods to detect pathogens
WO2022006424A2 (en) * 2020-07-02 2022-01-06 The Regents Of The University Of Californa Persistent memory t-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways
US11740240B2 (en) * 2020-07-20 2023-08-29 Bio-Rad Laboratories, Inc. Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor
US20220050105A1 (en) * 2020-08-12 2022-02-17 Boston Molecules, Inc. Method and apparatus for detecting viruses in biological samples
WO2022036337A1 (en) * 2020-08-13 2022-02-17 Diaclone Llc Compositions and methods for recombinant polypeptide mimicking sars-cov-2 nucleocapsid protein (np)
CN112760420B (en) * 2021-02-05 2023-05-26 中国科学院长春应用化学研究所 Primer, probe and kit for detecting novel coronavirus SARS-CoV-2
WO2022241256A1 (en) * 2021-05-13 2022-11-17 Serimmune Inc. Serum antibody profiling for leptospirosis
US20230176072A1 (en) * 2021-12-02 2023-06-08 Zymeron Corporation Novel Immunoassay Platform for the Serological Discrimination of Closely Related Viruses

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480764B1 (en) 1980-04-18 1985-10-04 Rhone Poulenc Spec Chim LATEX OF MAGNETIC POLYMERS AND PREPARATION METHOD
NO155316C (en) 1982-04-23 1987-03-11 Sintef PROCEDURE FOR MAKING MAGNETIC POLYMER PARTICLES.
GB2125047B (en) 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
EP0118551A1 (en) 1982-09-15 1984-09-19 Collaborative Research Inc. Production of interferon in yeast by use of invertase promoter
HU206897B (en) 1985-10-25 1993-01-28 Zymogenetics Inc Process for utilizing bar-1 gen for selecting strange proteins
US5879926A (en) 1989-03-31 1999-03-09 Transgene S.A. Yeast strains for the production of mature heterologous proteins, especially hirudin
FR2645160B1 (en) 1989-03-31 1992-10-02 Rhone Poulenc Chimie
JP2979414B2 (en) 1989-09-29 1999-11-15 富士レビオ株式会社 Magnetic particles and immunoassay using the same
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9224888D0 (en) * 1992-11-27 1993-01-13 Univ Singapore Monoclonal antibody
DK82893D0 (en) 1993-07-08 1993-07-08 Novo Nordisk As PEPTIDE
FR2714830B1 (en) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition containing nucleic acids, preparation and uses.
FR2715847B1 (en) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition containing nucleic acids, preparation and uses.
FR2727679B1 (en) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa NEW TRANSFECTION AGENTS AND THEIR PHARMACEUTICAL APPLICATIONS
FR2730637B1 (en) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACIDS, AND USES THEREOF
US5981180A (en) 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
CA2227895C (en) 1995-10-11 2012-07-17 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
US5736330A (en) 1995-10-11 1998-04-07 Luminex Corporation Method and compositions for flow cytometric determination of DNA sequences
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6449562B1 (en) 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
CA2306501C (en) 1997-10-14 2011-03-29 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
EP1049807B1 (en) 1998-01-22 2003-05-07 Luminex Corporation Microparticles with multiple fluorescent signals
FR2777909B1 (en) 1998-04-24 2002-08-02 Pasteur Institut USE OF TRIPLEX-STRUCTURED DNA SEQUENCES FOR THE TRANSFER OF NUCLEOTID SEQUENCES IN CELLS, RECOMBINANT VECTORS CONTAINING THESE TRIPLEX SEQUENCES
ATE412184T1 (en) * 1999-08-17 2008-11-15 Luminex Corp METHOD FOR ANALYZING A PLURALITY OF SAMPLES OF DIFFERENT ORIGINS FOR ONE ANALYTE
EP1208382B1 (en) 1999-08-17 2006-04-26 Luminex Corporation Encapsulation of fluorescent particles
DK1092779T3 (en) 1999-10-11 2010-02-15 Pasteur Institut Lentivirus virus vectors for the preparation of immunotherapeutic preparations
US9709559B2 (en) * 2000-06-21 2017-07-18 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
US6689615B1 (en) * 2000-10-04 2004-02-10 James Murto Methods and devices for processing blood samples
AU2002251257B2 (en) * 2001-04-10 2007-08-30 Ecole Polytechnique Federale De Lausanne Methods of Using O6-alkylguanine-DNA Alkyltransferases
ES2329986T3 (en) * 2001-09-06 2009-12-03 Rapid Micro Biosystems Inc QUICK DETECTION OF CELLS IN REPLICATION.
US6682507B2 (en) 2002-02-20 2004-01-27 Doug's Kangaroo Pouch, Llc User wearable device having sterile environment for connecting peritoneal dialysis tubes
WO2004040263A2 (en) * 2002-10-31 2004-05-13 Health Research, Inc. Diagnostic test for west nile virus
US7067258B2 (en) * 2002-04-30 2006-06-27 Merck & Co., Inc. Human papillomavirus multiplexed assay
EP1546370A1 (en) 2002-10-03 2005-06-29 Ecole Polytechnique Federale De Lausanne (Epfl) Protein labelling with o6-alkylguanine-dna alkyltransferase
CN1720332A (en) 2002-10-03 2006-01-11 洛桑生态综合技术联合公司 Substrates for O6-alkylguanine-DNA alkyltransferase
WO2004036220A1 (en) 2002-10-18 2004-04-29 Rescom Gmbh Diagnosis of glaucoma by complex autoantibody repertoires in body fluids
JP2007526282A (en) 2004-03-02 2007-09-13 ウペエフエル・エコル・ポリテクニック・フェデラル・ドゥ・ローザンヌ O6-alkylguanine DNA alkyltransferase specific substrate
CA2495138C (en) * 2005-01-20 2012-10-23 Alison Jane Basile Multiplexed analysis for determining a serodiagnosis of viral infection
CA2605160A1 (en) * 2005-04-05 2006-10-05 Allergan, Inc. Clostridial toxin activity assays
WO2006107921A2 (en) * 2005-04-05 2006-10-12 Allergan, Inc. Lipophilic dye-based fret assays for clostridial toxin activity
WO2006114409A1 (en) 2005-04-27 2006-11-02 Covalys Biosciences Ag Pyrimidines reacting with o6-alkylguanine-dna alkyltransferase
EP1882688A1 (en) * 2006-07-25 2008-01-30 EPFL Ecole Polytechnique Fédérale de Lausanne Labelling of fusion proteins with synthetic probes
CA2720247C (en) * 2008-03-31 2020-07-14 Pacific Biosciences Of California, Inc. Single molecule loading methods and compositions
FR2936245B1 (en) * 2008-09-23 2012-07-06 Cis Bio Int NOVEL O6-ALKYLGUANIN-DNA ALKYLTRANSFERASE SUBSTRATES AND MUTANTS THEREOF
CA2754980A1 (en) 2009-03-18 2010-09-23 Prometheus Laboratories Inc. Addressable antibody arrays and methods of use
WO2011118982A2 (en) * 2010-03-23 2011-09-29 주식회사 진진바이오 Hpv antibody screening method using fusion polypeptide hpv antigens
CN107090441A (en) * 2010-12-09 2017-08-25 巴斯德研究所 The method based on MGMT for obtaining high yield expression of recombinant proteins
JP6215223B2 (en) * 2011-12-09 2017-10-18 アンスティテュ・パストゥール Multiplex immunoscreening assay

Also Published As

Publication number Publication date
CN104114697A (en) 2014-10-22
WO2013164476A1 (en) 2013-11-07
CN104704117A (en) 2015-06-10
JP2015517649A (en) 2015-06-22
EP2844748B1 (en) 2018-07-11
US10352930B2 (en) 2019-07-16
JP6215223B2 (en) 2017-10-18
CA2872127A1 (en) 2013-11-07
MX2014006870A (en) 2014-11-25
AU2013255744A1 (en) 2014-11-13
CN104704117B (en) 2018-08-03
EP2788478B1 (en) 2017-08-23
US9638692B2 (en) 2017-05-02
AU2012350229A1 (en) 2014-07-17
EP2844748A1 (en) 2015-03-11
AU2012350229B2 (en) 2018-03-22
WO2013083847A2 (en) 2013-06-13
BR112014027465A2 (en) 2017-06-27
DK2788478T3 (en) 2017-10-09
WO2013083847A3 (en) 2013-08-01
BR112014027465B1 (en) 2022-07-12
KR20140113937A (en) 2014-09-25
US20140274762A1 (en) 2014-09-18
JP6351571B2 (en) 2018-07-04
EP2788478A2 (en) 2014-10-15
BR112014013745A2 (en) 2017-12-12
CA2857998A1 (en) 2013-06-13
NO2788478T3 (en) 2018-01-20
US10197562B2 (en) 2019-02-05
US20180038852A1 (en) 2018-02-08
US10209248B2 (en) 2019-02-19
KR102007061B1 (en) 2019-08-02
ES2648899T3 (en) 2018-01-08
KR20150016941A (en) 2015-02-13
BR112014027465A8 (en) 2021-06-29
NZ701380A (en) 2016-03-31
US20170336412A1 (en) 2017-11-23
MX2014013417A (en) 2014-11-26
MX349562B (en) 2017-08-02
SG11201407167RA (en) 2014-11-27
US20170276672A1 (en) 2017-09-28
CA2857998C (en) 2021-01-19
JP2015500989A (en) 2015-01-08
BR112014013745B1 (en) 2022-06-14
KR102049623B1 (en) 2019-11-28
MX357087B (en) 2018-06-25
US20150099656A1 (en) 2015-04-09
US10119967B2 (en) 2018-11-06

Similar Documents

Publication Publication Date Title
SG11201403010TA (en) Multiplex immuno screening assay
GB2492268B (en) Immobilised-bead multiplex assay
ZA201209004B (en) Anti-fgfr2 antibodies
GB201108678D0 (en) Multiplexed proximity ligation assay
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
HK1194388A1 (en) Anti-notch1 antibodies
EP2542576A4 (en) Methods for screening antibodies
PL2603528T3 (en) Fab-glycosylated antibodies
GB201020738D0 (en) Antibodies
GB201002238D0 (en) Antibodies
ZA201302459B (en) Antibodies
PL2729809T3 (en) Assay
EP2627788A4 (en) Microvesicle-based assays
GB201106615D0 (en) Assay
GB201021711D0 (en) Assay
GB201004306D0 (en) Assay
GB201002382D0 (en) Assay
GB201102659D0 (en) Assay
GB201216122D0 (en) Screening assay
GB201121265D0 (en) Assay
GB201113101D0 (en) Assay
GB201002785D0 (en) Multiplex assay
GB201105572D0 (en) Screening method-III
GB201121573D0 (en) Assay